EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib
It is intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of Mortality, But Not All Cancer Sites Present the Same Risk
Findings from a large retrospective cohort study
FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Evidence for efficacy is based on the results from the POLARIX study
Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with Conventional Radiotherapy for Localised Vertebral Metastases
Findings from the NRG/RTOG 0631 study
FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection in Patients with Haematologic Malignancies
Safety and efficacy were evaluated in Study P0501
Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare Cancers
Final results of the ROAR study
Survivors of Childhood Cancer are at Excess Risk of Late Mortality Even 40 Years from Diagnosis
Modifiable lifestyle and cardiovascular risk factors associated with reduced risk for late mortality should be part of future interventions
Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Advanced Endometrial Cancer
Findings from a final prespecified overall survival analysis from the Study 309/KEYNOTE-775
Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in CLDN18.2-positive, HER2-negative Advanced Gastric or Gastro-Oesophageal Junction Cancer
Findings from the SPOTLIGHT study
RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and OS in Patients with Newly Diagnosed and Recurrent Glioblastoma
More complex imaging criteria to assess treatment response in neuro-oncology do not improve the predictive value of the original RANO criteria
Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of Follow-Up Treatment Compared to Community Health Days
Findings from the ASPIRE Mayuge, cluster-randomised study
No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as First-Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Findings from the CheckMate 714 study